Related Experiment Videos
Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma
K M Hebeda1, M T Huizing, P A Brouwer
1Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
Summary
Photodynamic therapy (PDT) showed high response rates for AIDS-related Kaposi's sarcoma (KS) but caused severe side effects and poor cosmetic outcomes. The treatment is not recommended due to these significant drawbacks.
Area of Science:
- Oncology
- Dermatology
- Photomedicine
Background:
- Acquired immune deficiency syndrome (AIDS)-related cutaneous Kaposi's sarcoma (KS) is a significant concern.
- Photodynamic therapy (PDT) is explored as a local treatment option.
Purpose of the Study:
- To evaluate the efficacy and safety of photodynamic therapy (PDT) for treating AIDS-related cutaneous Kaposi's sarcoma (KS).
Main Methods:
- Nine PDT treatments were administered to eight HIV-positive homosexual men.
- Patients received 2 mg/kg Photofrin followed by either 120 J/cm2 or 70 J/cm2 of 630 nm laser light.
- 83 lesions were evaluated for response over a 3-8 month follow-up period.
Main Results:
- Overall patient response rates ranged from 50-100% (120 J/cm2) and 83.3-90.3% (70 J/cm2), with a median response duration of 3 months.
- Tumors on the head showed higher response rates compared to trunk or extremity lesions (p = 0.005 and p = 0.015).
- Larger KS lesions had a lower probability of complete response (p = 0.047).
- Significant side effects included pain, blisters, edema, and unsatisfactory cosmetic results (scars, hyperpigmentation).
Conclusions:
- While PDT demonstrates high response rates for cutaneous KS, the tested light doses (70-120 J/cm2) are not recommended.
- Severe side effects and poor cosmetic outcomes limit the clinical utility of this PDT regimen for KS treatment.